Abbott Laboratories $ABT Stock Holdings Lifted by Covea Finance

Covea Finance increased its holdings in Abbott Laboratories (NYSE:ABT) by 3.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 368,954 shares of the healthcare product maker’s stock after buying an additional 13,900 shares during the period. Abbott Laboratories comprises approximately 1.5% of Covea Finance’s holdings, making the stock its 14th biggest position. Covea Finance’s holdings in Abbott Laboratories were worth $46,226,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABT. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $31,000. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth approximately $32,000. Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories during the 3rd quarter valued at approximately $33,000. Finally, Copia Wealth Management acquired a new position in Abbott Laboratories during the 3rd quarter valued at approximately $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Leerink Partners reduced their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Finally, Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Insider Activity at Abbott Laboratories

In other news, EVP Elizabeth C. Cushman sold 263 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the sale, the executive vice president owned 38,573 shares of the company’s stock, valued at $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 1.5%

Shares of NYSE ABT opened at $105.58 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $139.06. The company has a market cap of $183.88 billion, a price-to-earnings ratio of 28.38, a P/E/G ratio of 1.71 and a beta of 0.74. The business has a fifty day simple moving average of $112.75 and a 200-day simple moving average of $123.09.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the company earned $1.34 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.